<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00376376</url>
  </required_header>
  <id_info>
    <org_study_id>MSU 06-496F</org_study_id>
    <nct_id>NCT00376376</nct_id>
  </id_info>
  <brief_title>Urinary Bactericidal Activity of 4 Doses of Levofloxacin Against Fluoroquinolone-Resistant E. Coli</brief_title>
  <official_title>Urinary Bactericidal Activity of 4 Doses of Levofloxacin (250, 500, &amp;750, and 1000 mg) Against Fluoroquinolone-Resistant E. Coli</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michigan State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PriCara, Unit of Ortho-McNeil, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Michigan State University</source>
  <brief_summary>
    <textblock>
      Single-dose studies of a fluoroquinolone are indicative of their antimicrobial activity since&#xD;
      little accumulation occurs with multiple doses. Single-dose studies have been utilized to&#xD;
      determine drug concentrations and time kill activity in serum, urine, and respiratory&#xD;
      tissues.&#xD;
&#xD;
      The purpose of this study is to evaluate the Urine Bactericidal Activity (UBA) of&#xD;
      levofloxacin (250, 500, 750, and 1000 mg) against FQ-resistant, ESBL positive E. coli&#xD;
      isolates. In addition, a susceptibility breakpoint concentration in the urine can also be&#xD;
      established for each dose of levofloxacin. Furthermore, urine concentrations and serum&#xD;
      pharmacokinetic parameters of levofloxacin can be determined.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects: -10 healthy (from medical history) adult male or female volunteers&#xD;
&#xD;
        -  Normal body weight (within 20 %)&#xD;
&#xD;
        -  Age range: 18-60&#xD;
&#xD;
        -  Not taking any other restricted medications (ie. antibiotics)&#xD;
&#xD;
      Drug : all drugs are a single dose given after a 12 hour fast&#xD;
&#xD;
        -  1000 mg.levofloxacin&#xD;
&#xD;
        -  750 mg. levofloxacin&#xD;
&#xD;
        -  500 mg levofloxacin&#xD;
&#xD;
        -  250 mg levofloxacin&#xD;
&#xD;
      Levofloxacin Pharmacokinetic Study:&#xD;
&#xD;
      A serum sample will be obtained prior to and at 1.5 (peak), 4.0, 8.0, 12 (50% of interval)&#xD;
      and 24 (100% of interval) hours after each single dose of levofloxacin (6 time points).&#xD;
&#xD;
      Levels will be determined by an HPLC assay.&#xD;
&#xD;
      Urine Pharmacodynamic Study:&#xD;
&#xD;
      A urine sample will be obtained prior to and at 1.5 (peak), 4, 8, 12 (50% of interval), and&#xD;
      24 (100% of interval) hours after a single dose of each dose of levofloxacin.&#xD;
&#xD;
      A urine pH will be run on each sample.&#xD;
&#xD;
      All urine levels will be determined by a validated HPLC assay.&#xD;
&#xD;
      Study Isolates: E. coli (TRUST isolates):&#xD;
&#xD;
      Levofloxacin MICs:&#xD;
&#xD;
        -  0.125 (sensitive)&#xD;
&#xD;
        -  4.0 (intermediate)&#xD;
&#xD;
        -  8.0 (resistant)&#xD;
&#xD;
        -  16.0 (resistant)&#xD;
&#xD;
        -  32.0 (resistant)&#xD;
&#xD;
        -  64.0 (resistant)&#xD;
&#xD;
      This MIC range of E. coli isolates should be able to define a levofloxacin susceptibility&#xD;
      breakpoint for urinary pathogens at each dose studied.&#xD;
&#xD;
      Urine Cidal Activity: Urine samples will be tested against each of the study isolates. A&#xD;
      maximum urine cidal titer will be determined for each urine. The median titer at each time&#xD;
      period (10 subjects) will determine the urine cidal activity.&#xD;
&#xD;
      The duration of cidal activity for each isolate will be determined and plotted. A 12-h&#xD;
      duration will be considered the minimum time necessary for prolonged Urine Bactericidal&#xD;
      Activity (MIC breakpoints).&#xD;
&#xD;
      Safety: All patients will be monitored for side effects during the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date>November 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluate the Urine Bactericidal Activity (UBA) of different doses and urine levels of levofloxacin against drug-resistant bacteria.</measure>
  </primary_outcome>
  <enrollment>10</enrollment>
  <condition>Healthy Volunteers</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levofloxacin at 250, 500, 750, and 1000 mg doses</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy (from medical history) adult male or female volunteers&#xD;
&#xD;
          -  Normal body weight (within 20 %)&#xD;
&#xD;
          -  Age range: 18-60&#xD;
&#xD;
          -  Not taking any other restricted medications (ie. antibiotics)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-healthy volunteers&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  volunteers on other antibiotics&#xD;
&#xD;
          -  body weight over 20% of normal&#xD;
&#xD;
          -  Age &lt;18 or &gt;60&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary E. Stein, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michigan State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Havlichek, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michigan State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michigan State University- Dept. of Medicine</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>September 13, 2006</study_first_submitted>
  <study_first_submitted_qc>September 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2006</study_first_posted>
  <last_update_submitted>November 25, 2008</last_update_submitted>
  <last_update_submitted_qc>November 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2008</last_update_posted>
  <keyword>levofloxacin</keyword>
  <keyword>pharmacodynamic</keyword>
  <keyword>bactericidal</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

